{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:59:17Z","timestamp":1721066357946},"reference-count":10,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Laryngol. Otol."],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0022215120000122_sec_a1\" sec-type=\"other\"><jats:title>Objective<\/jats:title><jats:p>Epistaxis is a common ENT presentation. The British National Formulary lists epistaxis as a common side effect of atorvastatin. This study aimed to better understand the relationship between epistaxis and atorvastatin use, and determine whether ENT doctors are aware of its side effect profile.<\/jats:p><\/jats:sec><jats:sec id=\"S0022215120000122_sec_a2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis over 10 months identified 100 individuals who presented to hospital with epistaxis. A questionnaire of 24 ENT registrars was undertaken.<\/jats:p><\/jats:sec><jats:sec id=\"S0022215120000122_sec_a3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Of the 100 patients admitted with epistaxis, 27 were receiving atorvastatin and 21 simvastatin. None of the 24 ENT registrars were aware that epistaxis was a listed common side effect of atorvastatin.<\/jats:p><\/jats:sec><jats:sec id=\"S0022215120000122_sec_a4\" sec-type=\"conclusions\"><jats:title>Conclusion<\/jats:title><jats:p>There was no apparent difference in the proportion of patients admitted with epistaxis taking atorvastatin versus simvastatin. Epistaxis is an unknown side effect of atorvastatin; doctors have an obligation to be aware of the pharmaceutical literature and to consider alternatives, particularly in re-admissions cases.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0022215120000122","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T08:50:41Z","timestamp":1579683041000},"page":"138-140","source":"Crossref","is-referenced-by-count":2,"title":["Epistaxis and atorvastatin: is there an association and are clinicians aware? A retrospective audit of 100 patients"],"prefix":"10.1017","volume":"134","author":[{"given":"E","family":"Heward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A S","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"S0022215120000122_ref10","unstructured":"10 Electronic Medicines Compendium. Lipitor - Summaries of Product Characteristics. In: https:\/\/www.medicines.org.uk\/emc\/product\/1059\/smpc [4 October 2019]"},{"key":"S0022215120000122_ref9","doi-asserted-by":"publisher","DOI":"10.2165\/0129784-200808060-00004"},{"key":"S0022215120000122_ref4","unstructured":"4 BMJ Group and the Royal Pharmaceutical Society of Great Britain 2018. British National Formulary. In: https:\/\/www.medicinescomplete.com\/#\/content\/bnf\/_138735514 [5 September 5 2018]"},{"key":"S0022215120000122_ref1","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215110001921"},{"key":"S0022215120000122_ref2","doi-asserted-by":"publisher","DOI":"10.1177\/0194599817721445"},{"key":"S0022215120000122_ref3","doi-asserted-by":"publisher","DOI":"10.1017\/S002221511700202X"},{"key":"S0022215120000122_ref5","unstructured":"5 Pfizer Medical Information. Lipitor Adverse Reactions. In: https:\/\/www.pfizermedicalinformation.com\/en-us\/lipitor\/adverse-reactions [4 October 2019]"},{"key":"S0022215120000122_ref6","unstructured":"6 US Food and Drug Administration. Lipitor. In: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020702s057lbl.pdf [4 October 2019]"},{"key":"S0022215120000122_ref7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059344"},{"key":"S0022215120000122_ref8","first-page":"E98","article-title":"Adverse side effects of statins in the oral cavity","volume":"13","author":"Cruz","year":"2008","journal-title":"Med Oral Patol Oral Cir Bucal"}],"container-title":["The Journal of Laryngology &amp; Otology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0022215120000122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T15:29:51Z","timestamp":1584026991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0022215120000122\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0022215120000122"],"URL":"https:\/\/doi.org\/10.1017\/s0022215120000122","relation":{},"ISSN":["0022-2151","1748-5460"],"issn-type":[{"value":"0022-2151","type":"print"},{"value":"1748-5460","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]}}}